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Aims: Our study focuses on the design and synthesis of a new piperazinic derivate, 4-(1-phenyl-1h-Pyrazol-
4-Ylmethyl)-Piperazine-1-Carboxylic Acid Ethyl ester (LQFM008), and evaluation of its anxiolytic-like proﬁle
in Swiss mice.
Main methods: LQFM008 was evaluated in a screening test of the central nervous system including the rota-
rod, sodium pentobarbital-induced sleep, open ﬁeld, elevated plus maze and light–dark box tests.
Key ﬁndings: LQFM008 induced convulsions at the dose of 1.1 mmol/kg (i.p., s.c. or p.o.). LQFM008 up to
400 μmol/kg had no effect in the rota rod test. In the open ﬁeld test, LQFM008 increased the number of cross-
ings and the time spent at the central area as well as the sleeping time in sodium pentobarbital-induced
sleep. In the elevated plus maze and light–dark box tests, this compound showed an anxiolytic-like activity.
This anxiolytic-like activity was antagonized by NAN-190 (5-HT1A antagonist) but not by ﬂumazenil (benzo-
diazepine antagonist).
Signiﬁcance: The compound LQFM008 showed anxiolytic-like activity which may involve serotonergic
pathway.© 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Anxiety is a normal psychological and physiological state charac-
terized by somatic, emotional, cognitive and behavioral components,
being necessary for the survival of animals as well as human beings.
However, when that feeling of anticipation present at levels higher
than those considered normal, the anxiety becomes pathological
and has to be treated (Schmitt, 2003).
The drugs most used in the treatment of generalized anxiety are
the benzodiazepine, a positive modulator of GABA transmission, and
the buspirone, an anxio-selective drug which is a partial agonist of
serotoninergic receptor type 1A (5-HT1A) (Andreatini et al., 2001;
Clement and Chapouthier, 1998; Katzman, 2011).
Buspirone is a piperazine derivative; piperazine compounds con-
stitute a very large chemical class and some of these compounds
have the ability to cross the blood–brain barrier due to the small
size and the lipophilic nature of their molecules. Thus, somee Goiás, Instituto de Ciências
131, 74001-970, Goiânia, GO,
.
vier OA license.piperazine derivatives promote activity upon the central nervous sys-
tem and are used in the treatment of various mental disorders, in-
cluding anxiety disorders, Alzheimer's disease, psychosis and
depression (Katzman, 2011; Menegatti et al., 2003; Papakostas and
Fava, 2007; Sadashiva et al., 2006).
In order to explore the central pharmacological activity of the pi-
perazine derivatives, as well as to perform a quicker synthesis and
to obtain simpler compounds, this paper proposes the design, syn-
thesis and evaluation of the central pharmacological activity of the
new piperazine derivative 4-(1-phenyl-1H-pyrazol-4-ylmethyl)-
piperazine-1-carboxylic acid ethyl ester (LQFM008) in mouse be-
havioral models.
Material and methods
Chemical synthesis
The synthetic route planned to achieve the new piperazinic deri-
vate LQFM008 (7) (Fig. 1) consists of three stages: ﬁrst, the
1-phenyl-1H-pyrazole (3) was synthesized through the classical
method described by Finar and Hurlock (1957), but the chemoselec-
tive and regiospeciﬁc formylations of 1-phenyl-1H-pyrazoles were
performed under Duff's conditions (Johansson et al., 2003; Lalehzari
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Fig. 1. The synthetic route planned to achieve the new piperazinic derivate 4-(1-phenyl-1H-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester (LQFM008; 7).
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sisted of thereductiveaminationof formylphenylpirazole(5) toobtain
the 4-(1-phenyl-1H-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid
ethyl ester (LQFM008; 7); this step was performed under reﬂux for
2–4 h with 0.7 mmol of phenyl pirazole (5), 0.7 mL of ethyl N-
piperazinecarboxylate (6),7dropsof aceticacid,4.07 mmolofNaCNBH3
and 2.5 mL ofmethanol (Luo et al., 2004).
The melting points were determined with resonance (1H NMR)
and were determined in deuterated chloroform containing a Gehaka
PF1500®. Protonmagnetic ca. 1.0% tetramethylsilane as internal stan-
dard in a Bruker Avance® 500. Carbonmagnetic resonance (13C NMR)
was determined with the same spectrometer described above at
125 MHz, using deuterated chloroform containing ca. 1.0% tetra-
methylsilane. Infrared (IR) spectra were obtained with a Perkin-
Elmer Spectrum BXII FT-IR® spectrophotometer using potassium
bromide plates.
The progress of all reactions was monitored by TLC performed on
aluminum sheets which are precoated with silica gel 60 (F 254, What-
man®) to a thickness of 0.2 mm. The mobile phase was n-hexane:
ethyl acetate (70:30). The developed chromatograms were viewed
under ultraviolet light at 254 nm.1-Phenyl-1H-pyrazole (3)
Reaction condensation between phenyl hydrazine (1) and 1,1,3,3,
tetrametoxypropane (2) in 98% yield, as red oil, Rf=0.48 (n-hexane:
ethyl acetate, 70:30). IR (liquid ﬁlm) cm−1: 3447–3124 ( νC\H);
1598–1494 ( νC_C and C_N); 1H NMR (500 MHz) CDCl3/TMS (δ):
7.73 (dd, J=1.9 and 0.5 Hz, H-3); 6.47 (dd, J=2.4 and 1.9 Hz, H-4);
7.93 (dd, 2.4 and 0.5 Hz, H-5); 7.69 (dddd, 7.5, 2.2, 1.6 and 0.7 Hz,
H-2′); 7.45 (dddd, 7.5, 7.4, 1.9 and 0.9 Hz, H-3′); 7.29 (tdd, 7.4,1.6
and 1.2 Hz, H-4′); 7.45 (ddd, 7.4, 7.2, 1.9 and 0.7 Hz, H-5′) and 7.69
(ddd, 7.2, 2.2, 1.2 and 0.9 Hz, H-6′). 13C NMR (125 MHz) CDCl3/TMS
(δ): 141.1 (C-3); 107.7 (C-4); 126.6 (C-5); 140.1 (C-1′); 119.2
(C-2′); 129.3 (C-3′); 126.4 (C-4′); 129.3 (C-5′) and 119.2 (C-6′).1-Phenyl-1H-pyrazole-4-carbaldeyde (5)
Derivate (5) was obtained in 58.28% yield, as a brown solid, mp
61–68 °C, Rf=0.72 (n-hexane:ethyl acetate, 70:30). IR (KBr) cm−1:
3126 ( νC\H); 1681 ( νC_O); 1546–1507 (νC_C and C_N); 1H
NMR (500 MHz) CDCl3/TMS (δ): 8.17 (d, 0.5 Hz, H-3); 8.44 (d,
0.5 Hz, H-5); 7.73 (ddd, 7.4, 2.1 and 1.2 Hz, H-2′); 7.51 (dddd, 7.4,
7.0, 2.0 and 1.9 Hz, H-3′); 7.39 (tt, 7.0 and 1.2 Hz, H-4′); 7.51 (ddd,
8.2, 7.0 and 1.9 Hz, H-5′); 7.73 (dddd, 8.2, 2.1, 2.0 and 1.2 Hz, H-6′)
and 9.97 (s, CHO). 13C NMR (125 MHz) CDCl3/TMS (δ): 141.7 (C-3);
125.6 (C-4); 130.0 (C-5); 139.0 (C-1′); 119.8 (C-2′); 129.8 (C-3′);
127.9 (C-4′), 129.8 (C-5′); 119.8 (C-6′) and 184.2 (CHO).
4-(1-Phenyl-1H-pyrazole-4yl methyl)-piperazine-1-carboxylic acid
ethyl ester (LQFM008, 7)
Reductive amination between phenyl pirazole (5) and ethyl N-
piperazine carboxylate (6) in 55% yield, as yellow solid, mp 98–
100 °C (n-hexane:ethyl acetate, 70:30). IR (KBr) cm−1: 3115
(νC\H); 1505–1340 (νC_C and C_N); 1607 (νC_O); 1270
(νC_O); 1H NMR (500 MHz) CDCl3/TMS (δ): 7.87 (1H, s, H-5); 7.67
(2 H, dd, J=1.4 and J=8.8 Hz, H-2′ and 6′); 7.64 (1H, s, H-3); 7.46–
7.43 (2 H, dd, J=7.6 and J=8.0 Hz, H-3′ and 5′); 7.29–7.26 (1H, H-
4′); 4.12 (2 H, dd, J=7.0 Hz, H-6); 3.05 (2 H, s, H-14); 3.52–3.47
(4 H, m, H-9 and 11); 2.47–2.41 (4 H, m, H-8 e 12); 1.25 (3 H,
J=7.0 Hz, H-15); 13C NMR (125 MHz) CDCl3/TMS (δ): 155.3 (1C, C-
13); 141.9 (1C, C-3); 140.1 (1C, C-1′); 129.4 (2C, C-3′ and 5′); 126.4
(1C, C-5′); 126.2 (1C, C-4′); 119.0 (1C, C-4); 118.4 (2C, C-6′ and 2′);
61.1 (1C, C-14); 52.4 (1C, C-6); 52.2 (2C, C-8 and 12); 43.4 (2C, C-9
and 11); and 29.6 (1C, C-15).
Pharmacological evaluation
Drugs
Diazepam (Diazepan®, Cristália, Brazil), sodium pentobarbital
(Sigma Chemical Co., USA), polisobarte 80 (Tween 80 — Synth,
EUA), ﬂumazenil (União Química, Brazil), buspirone (Libbs, Brazil),
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piperazine (NAN-190 — Chemical Co., USA) were used in the present
study. It is well known that benzodiazepines act as anxiolytic-like at
low doses, and they also produce sedation and myorelaxant effect at
higher doses (Novas et al. 1988), thereby, our group has used diaze-
pam 3.51 μmol/kg (1 mg/kg) as the standard drug for anxiolytic-like
effect, and diazepam 17.51 μmol/kg (5 mg/kg) as the standard drug
for sedative and myorelaxant effects.
Animals
Adult male Swiss mice weighing approximately 30 g were used
in all experiments. The animals were provided by the Central Ani-
mal House of Federal University of Goiás (Universidade Federal de
Goiás — UFG); they were housed in groups of 20 mice/cage and
were kept in a room with controlled temperature (25±1 °C) and
lighting (light/dark cycle of 12 h, light on at 7 am), with food and
water ad libitum. The animals were kept in the laboratory for an ad-
aptation period of at least 1 h before the experiments. The tests are
usually conducted between 9:00 a.m. to 3:00 p.m. All experiments
were carried out in accordance with the principles of ethics and an-
imal welfare recommended by the Brazilian Law (# 11.794 — 10/08/
2008) and the experimental protocols were approved by the Ethics
Commission of the UFG (no. 104/11).
Effects on gross behavior or Irwin test
This test was used to assess preliminary drug effects on mice be-
havior and toxicity, and also to determine effective dose range. Ex-
perimental groups of mice (n=3) were treated orally (p.o.),
intraperitoneally (i.p.) or subcutaneously (s.c.) with LQFM008 at
the doses of 1.1 mmol/kg, 0.3 mmol/kg and 0.06 mmol/kg, whereas
control groups received vehicle (2% Tween-80, 10 mL/kg) by the
same routes. Animals were observed in free ambulation on a ﬂat
surface for 3 min, at 0, 5, 10, 20, 30 and 60 min, 4, 8, 24 and 48 h,
4 and 7 days after the treatment. The presence or absence of mortal-
ity, seizure, erection of the tail (Straub sign), sedation, excitation,
motor incoordination, abdominal torsion and spontaneous ambula-
tion was recorded. The observed effects were compiled using a stan-
dard pharmacological screening approach, adapted from that
described by Malone (1977).
Rota rod test
It is a test that permits the detection of potential neurotoxic and/
or muscle relaxing agents. Animals were trained previously (24 h be-
fore experiment) based on their capacity to maintain their balance
(for 2 min) on the rotating bar (12 rpm) with an axis of 3 cm in diam-
eter. For testing, the pre-trained animals (n=9/group) were treated
(p.o.) with vehicle (2% Tween-80, 10 mL/kg), LQFM008 at the doses
of 100, 200 and 400 μmol/kg, or diazepam 17.51 μmol/kg. The mice
were placed on the rota-rod after 60 min of treatments and the num-
ber of falls for up to 1 min and/or three falls were recorded (Dunham
and Miya, 1957).
Sodium pentobarbital-induced sleep test
It is a useful test for detecting agents with sedative effects. Groups
of mice (n=9/group) were pre-treated with vehicle (2% Tween-80,
10 mL/kg, p.o.), LQFM008 at the doses of 100, 200 and 400 μmol/kg
p.o., or diazepam 17.51 μmol/kg p.o. Sixty minutes after the treat-
ment, the animals received sodium pentobarbital (221.0 μmol/kg,
i.p.). Latency to induce sleep (loss of the righting reﬂex) and the du-
ration of the sleeping time (the time required to recover the righting
reﬂex) were recorded for each animal (Carlini and Burgos, 1979).
Open ﬁeld test
It is a useful test to assess mice ambulatory behavior and also de-
tect anxiolytic-like or anxiogenic-like agents. Sixty minutes after thetreatment (n=9) with vehicle (2% Tween-80, 10 mL/kg, p.o.),
LQFM008 at doses of 100, 200 and 400 μmol/kg p.o., diazepam 3.51
and 17.51 μmol/kg p.o., the animals were placed at the center of an
open ﬁeld arena. The apparatus consisted of a circular arena measur-
ing 36 (diameter)×20 cm (height), with the bottom divided into
eight squares of equal area. The number of squares crossed, number
of rearing behaviors, immobility time (s), number of crossings and
time (s) spent at the center of the arena were recorded in a 5 min ses-
sion (Archer, 1973; Siegel, 1946).
Elevated plus maze test
It is a test validated for the detection of potentially effective
anxiolytic-like or anxiogenic-like agents. Experimental groups of 9
mice were treated (p.o.) with vehicle (2% Tween 80, 10 mL/kg),
LQFM008 (25, 50, 100, 200 or 400 μmol/kg) or diazepam
(3.51 μmol/kg). The acrylic plus maze apparatus consisted of two
open arms (30×5 cm) and two closed arms of the same size but
with end and side walls measuring 25 cm in height, the arms were
connected by a central 5×5 cm area, purchased from Insight Scientif-
ic Equipments — Brazil (model EP 150®). Sixty minutes after the
treatment, animals were placed individually at the center of the ele-
vated plus maze with their nose facing the direction of one of the
enclosed arms, and observed for 5 min (Lister, 1987; Pellow et al.,
1985). The test was carried out under a red light (15 W) and was
fully recorded for later analysis. Parameters such as the time spent
in the central platform, the number of entries and the time spent in
the open and enclosed arms of elevated plus maze were used as a
measure of anxiety. Anxiolytic compounds reduce the animal's aver-
sion to the open arms and promote its exploration.
Light–dark box test
This test is one of the most frequently employed models for the as-
sessment of the anxiolytic-like or anxiogenic-like activity of a novel
agent. Sixty minutes after the treatment with vehicle (2% Tween 80,
10 mL/kg, p.o.), LQFM008 (25, 50, 100, 200 or 400 μmol/kg, p.o.) or di-
azepam (3.51 μmol/kg, p.o.), the animals (n=9/group) were placed at
the center of the light area (20×26.5×26 cm) facing the opening
(7×7 cm) of the dark area (20×26.5×17.5 cm); the number of transi-
tions between the two compartments and the time spent in the light
area were recorded over a 5 min period (Crawley and Goodwin, 1980).
Inﬂuence of the time of treatment with LQFM008 in experimental tests of
anxiety
Animals were evaluated in the elevated plus maze and in the
light–dark box, 15, 30, 60 and 90 min after the treatment with
LQFM008 200 μmol/kg p.o.
Investigation of the putative underlying mechanisms involved in the
anxiolytic-like effect
The animals were pre-treated i.p. (n=9) with saline 0.9%, NAN-
190 1.3 μmol/kg (5-HT1A antagonist) and ﬂumazenil 6.6 μmol/kg
(benzodiazepine antagonist). After 30 min, the animals were treated
(p.o.) with vehicle (Tween 2.0%, 10 mL/kg), LQFM008 100 μmol/kg,
diazepam 3.51 μmol/kg p.o. and buspirone 26 μmol/kg p.o. After
60 min, they were submitted to the elevated plus maze test.
Statistical analysis
Results were expressed as means±standard error of mean
(SEM). Data was analyzed by one-way analysis of variance
(ANOVA) followed by Student–Newman–Keuls as the post-hoc
test. For data without normal distribution, analysis was performed
using Kruskal–Wallis's test followed by Dunn's test. Effects were
considered signiﬁcant at p≤0.05 (Sokal and Rohlf, 1981).
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Effects on gross behavior or Irwin test
LQFM008 at dose of 1.1 mmol/kg (p.o., i.p. or s.c.) induced gener-
alized convulsions 5 min after treatments. However, LQFM008 at the
doses of 0.3 and 0.06 mmol/kg (p.o., i.p. or s.c.) apparently decreased
the spontaneous ambulation 5 min after the treatments. Based on
these results, we opted for LQFM008 at the doses of 100, 200 and
400 μmol/kg to assess the subsequent pharmacological activities.
Rota rod test
The treatments with LQFM008 do not alter the number of falls as
compared to the control group (Table 1) and, as expected, the treat-
ment with diazepam 17.51 μmol/kg increased this parameter.
Sodium pentobarbital-induced sleep test
Treatment with LQFM008 100, 200 and 400 μmol/kg increased the
sleeping time (Fig. 2A), without any alteration signiﬁcant in the
sleeping latency (Fig. 2B). Diazepam 17.51 μmol/kg increased the
sleeping time and decreased the sleeping latency (Fig. 2).
Effect of LQFM008 in the experimental tests of anxiety
Open ﬁeld test
The treatments with LQFM008 had no effects on total crossing, im-
mobility time and rearing behavior, while the doses of 200 and
400 μmol/kg increase the time spent at the center and all the three
doses increase the crossings in the central area (Table 1). As expected,
diazepam 3.51 μmol/kg increases the time and crossings at the central
area, while the dose of 17.51 μmol/kg increased the immobility time
and decreased the total crossing and rearing behaviors.
Elevated plus maze test
Treatment with LQFM008, at the doses of 50, 100 and 200 μmol/
kg, increased the entries and time spent in open arms, 400 μmol/kg
increased only the number of entries; all doses of LQFM008 decreased
the time spent at the central platform (Fig. 3). Diazepam 3.51 μmol/kg
increased the entries and the time spent in open arms and decreased
the time spent in the central platform (Fig. 3).
Light–dark box test
Treatment with LQFM008 100 and 200 μmol/kg increased the
transitions and time spent in the light area while LQFM008Table 1
Effects of the LQFM008 in the open ﬁeld and rota-rod tests in mice.
Vehicle LQFM008
10 mL/kg 100 μmol/kg 200 μmol/kg
Open ﬁeld test
Crossings 82.88±6.05 90.83±5.46 91.00±4.13
Immobility 19.56±4.12 16.17±6.40 17.78±3.21
Rearings 47.25±3.81 48.00±5.30 49.00±3.35
%CrCe 43.41±1.26 54.42±2.21⁎ 54.19±2.60⁎
TCe 78.62±8.75 100.75±7.30 116.14±9.64⁎
Rota rod test
Number of falls 0.6±0.16 0.3±0.15 0.3±0.15
Data are expressed as mean±SEM, and were analyzed statistically using one-way ANOVA
expressed as mean±SEM and were analyzed statistically using Kruskal–Wallis test, follow
%CrCe, time spent in the center of the open ﬁeld — TCe.
⁎⁎ p≤0.01.
⁎⁎⁎ p≤0.001.
⁎ p≤0.05.400 μmol/kg increased only the time spent in the light area (Fig. 4).
Diazepam 3.51 μmol/kg increases these parameters (Fig. 4).
Inﬂuence of the time of treatment with LQFM008 in two experimental
tests of anxiety
LQFM008 200 μmol/kg showed an anxiolytic-like proﬁle, in the
elevated plus maze and light–dark box tests, only 60 and 90 min
after the treatment (Table 2).Diazepam
400 μmol/kg 3.51 μmol/kg 17.51 μmol/kg
83.14±8.10 90.52±8.06 52.00±12.84⁎⁎
13.67±1.74 15.25±3.65 166.50±23.91⁎⁎⁎
46.62±4.33 49.25±4.69 11.90±3.57⁎⁎⁎
55.81±1.16⁎ 57.69±1.58⁎⁎ 46.35±4.80
114.00±11.77⁎ 130.02±10.68⁎⁎ 70.83±6.26
0.4±0.16 0.6±0.70 2.3±0.37⁎
, followed by Student–Newman–Keuls as post-test. In the rota rod test, the data are
ed by Dunn's test as post-test. Number of crossings in the center of the open ﬁeld —
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LQFM008 anxiolytic-like effect
The anxiolytic-like effect was not signiﬁcantly decreased when
ﬂumazenil was injected before oral administration of LQFM008
100 μmol/kg. However, this effect was signiﬁcantly decreased when
the mice were pretreated with NAN-190. Flumazenil and NAN-190
per se did not show an effect but they antagonized anxiolytic effects
of diazepam and buspirone, respectively (Fig. 5).
Discussion
A novel piperazine derivative (LQFM008), with putative central
activities, was designed from clozapine by molecular simpliﬁcation
strategy. Considering the investigation of a new candidate to neuro-
active drugs, the initial parameters investigated were the effects on
gross behavior or Irwin test. Our results showed that the LQFM008 in-
duced generalized convulsions at the dose of 1.1 mmol/kg.
The treatments with this compound did not alter the number of
falls evaluated in the rota-rod; thus suggesting their non-interference
with motor coordination of the mice. This result is consistent with theprevious research on three phenylpiperazine derivatives by Neves et
al. (2010) who reported absence of alteration in motor coordination
of the experimental subject in the rota rod.
The sodium pentobarbital-induced sleep allows observation of pu-
tative depressant and/or stimulant activity of a given drug as a result
of synergism or antagonism to the depressant activity of sodium pen-
tobarbital. Depressant drugs reduce the latency and increase the
sleeping time, whereas the reverse holds true for stimulant drugs
(Carlini et al., 1986; Farkas et al., 2005). LQFM008, at different
doses, increased the duration of sleep induced by sodium pentobarbi-
tal without reducing the latency, which could suggest a central de-
pressant activity.
In order to investigate a speciﬁc central anxiolytic‐like activity, open
ﬁeld, elevated plus maze and light–dark box tests were performed.
The open ﬁeld test is used to assess the mice ambulatory behav-
ior and may also detect anxiolytic-like or anxiogenic-like agents
(Prut and Belzung, 2003). Animals treated with LQFM008, did not
show any change in the total crossings, the immobility time and
the number of rearing behavior, thereby suggesting no alteration
in motor coordination. Hence, in respect of these results, the appar-
ent reduction of spontaneous locomotion, seen in Irwin test, may be
false-positive. Meanwhile, the LQFM008 increase in preference for
central area of the open-ﬁeld both in the number of crossing and
the time spent suggests an anxiolytic-like activity. Meanwhile, dif-
ferent activities of piperazine derivatives have been reported in
the open ﬁeld test. Angrini et al. (1998) demonstrated that animals
treated with buspirone did not alter the preference for the center of
open-ﬁeld, but increased the immobility time, while Rex et al.
(1998) showed that locomotor activity of animals remained unal-
tered with ipsapirone treatment.
The elevated plus maze test is the most used test for the selection
of anxiolytic-like drug prototype (Han et al., 2009; Avgustinovich
et al., 2003). This test is an animal model that uses natural stimuli
such as fear of new, open and high spaces (Yu et al., 2007) as well
as the preference for enclosed spaces. LQFM008 increased the
Table 2
Effects of the compound LQFM008 200 μmol/kg on the elevated plus maze test and light–dark box tests, 15, 30, 60 and 90 min after treatments (p.o.) in mice.
Vehicle LQFM008 200 μmol/kg (p.o.)
10 mL/kg (p.o.) 15 min 30 min 60 min 90 min
Elevated plus maze test
Entries in open arms (%) 30.19±5.6 35.87±3.3 40.67±2.7 49.27±3.3* 52.19±6.2*
Time spent in open arms (%) 30.86±5.3 28.17±2.6 33.78±5.2 53.20±5.7* 52.25±8.5*
Time spent in central platform (%) 42.30±3.4 30.46±4.2 30.50±3.4 18.90±3.2** 23.06±4.1**
Light–dark box
Transitions number 6.71±1.0 10.43±0.6 10.00±1.3 15.00±1.1*** 18.50±2.1***
Time spent on light area (%) 13.50±1.6 17.27±3.0 19.78±4.1 36.93±2.7*** 42.67±2.4***
Data are expressed as mean±SEM. *p≤0.05, **p≤0.01 and ***p≤0.001, compared with the control group (one-way ANOVA followed by Student-Newman-Keuls' test).
915A.F. de Brito et al. / Life Sciences 90 (2012) 910–916number of entries and the time spent in the open arms, and decreased
the time spent in the central platform, corroborating the anxiolytic-
like effect earlier observed in the open ﬁeld.
In the light–dark box test, the anxiolytic-like activity is charac-
terized by decrease in aversion for light area, increase in exploratory
activity, increase in the time spent in the light area and in the num-
ber of transitions between both sides of the box (Chen et al., 2006;0
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Fig. 5. Effects of the pre-treatment with NAN-190 1.3 μmol/kg i.p. and ﬂumazenil 6.6 μmol/k
pirone 26 μmol/kg p.o. in the elevated plus maze. (A) Number of entries into the open arm
*p≤0.05, **p≤0.01, ***pb0.001, compared with the control group, and ##pb0.01, ###pb0.0
kg p.o., saline i.p. (vehicle) and diazepam 3.51 μmol/kg p.o. or saline i.p. (vehicle) and buspHoog, 1996). In this test, LQFM008 also showed an anxiolytic-like
effect by increasing the transitions and the time spent in the light
area as compared with the control group.
The anxiolytic-like activity of LQFM008 became evident at 60
and 90 min after the treatment. Interestingly, there was no notable
disparity between the treatment times in respect of the anxiolytic
effect observed. Hence, 60 min was chosen for the investigation ofFlumazenil + Vehicle
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NAN + Vehicle
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g i.p. on the effects of LQFM008 100 μmol/kg p.o., diazepam 3.51 μmol/kg p.o. and bus-
s, (B) time spent in the open arms (%), and (C) time spent in the central platform (%).
01, compared with the group treated with saline i.p. (vehicle) and LQFM008 100 μmol/
irone 26 μmol/kg p.o. (one-way ANOVA followed by Student–Newman–Keuls' test).
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anxiolytic-like activity.
In the study of mechanism of action, we proposed to investigate the
involvement of the benzodiazepine site and the serotonin receptor type
1A. Pre-treatmentwith ﬂumazenil (benzodiazepine antagonist) did not
antagonize the LQFM008 anxiolytic-like activity in the elevated plus
maze test, hence, excluding the benzodiazepine site in the LQFM008 ef-
fect. The pre-treatment with NAN-190 (a 5-HT1A antagonist) antago-
nized the LQFM008 anxiolytic-like effect, when compared with the
results observed after the treatment with LQFM008, thus, suggesting
the participation of 5-HT1A receptor in LQFM008 activity.
Although clinically the anxiolytic activity of 5HT1A agonists that act
on the somatodendritic autoreceptors in the dorsal raphe nucleus of
midbrain raphe is a consequence of their desensitization during repeat-
ed treatment over several days. Meanwhile, in rodent experimental
models, this anxiolytic activity can be observed after an acute treat-
ment, as observed in this study and, by Cao and Rodgers (1997),
Young and Johnson (1991) and Peng et al. (2004) that demonstrated
the anxiolytic-like activity of buspirone, a 5-HT1A partial agonist, in
the elevated plusmaze test and light–dark box tests after an acute treat-
ment. Moreover, several reports in the literature have associated
anxiolytic-like activity of piperazine derivatives to the involvement of
serotoninergic pathway (Avgustinovich et al., 2003; Bojarski et al.,
2006; Gray et al., 2009; Khatri et al., 2009; Paluchowska et al., 2007).
This result as a matter of fact does not necessarily exclude the in-
volvement of other binding site of GABA and other neurotransmitters
in LQFM008 anxiolytic-like effect. Future research will be targeted at
elucidating the interaction of this compound with monoamine reup-
take and metabolism.
Conclusions
The compound LQFM008 is a new piperazine derivative that has
an anxiolytic-like activity in different animal models without
compromising motor activity, and this activity seems to involve the
participation of 5-HT1A receptors.
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